Physician profile
James D Jensen
NPI 1043503568
$6,152.44
in general payments reported to CMS, 2019-2025
38 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $309 · 2021: $908 · 2022: $1,092 · 2023: $1,403 · 2024: $1,162 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,281 · Education: $285 · Entertainment: $23.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,280.72 |
| Education | $284.97 |
| Entertainment | $23.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $959.58 | 2019-2025 | Tremfya |
| Abbvie INC. | $792.77 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $453.22 | 2021-2024 | Winlevi, Odomzo, Blu-U |
| Novartis Pharmaceuticals Corporation | $449.86 | 2022-2025 | |
| Ucb, INC. | $379.19 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $369.34 | 2021-2025 | Opzelura |
| Genzyme Corporation | $327.58 | 2019-2025 | |
| Leo Pharma INC. | $318.66 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $232.74 | 2019-2025 | Dupixent, Libtayo |
| Organogenesis INC. | $220.22 | 2021-2025 | Puraply Wound Matrix, Simplimax, Cygnus Dual |
| Lilly USA, LLC | $203.92 | 2020-2025 | Taltz, Olumiant, Zepbound |
| Pfizer INC. | $183.59 | 2019-2023 | |
| Galderma Laboratories, L.P. | $167.32 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $126.83 | 2022-2023 | Sotyktu |
| Allergan, INC. | $113.13 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $106.66 | 2023-2025 | Zoryve |
| Biofrontera INC. | $106.47 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $103.11 | 2019-2023 | Seysara |
| Organon LLC | $76.75 | 2023-2025 | Vtama, Hadlima |
| Amgen INC. | $68.39 | 2021-2024 | Otezla |
| Vyne Pharmaceuticals INC. | $62.44 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.52 | 2021-2025 | Cabtreo |
| Kerecis Limited | $47.34 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Boston Scientific Corporation | $42.49 | 2022-2024 | Varithena Administration Pack |
| Dermira, INC. | $28.81 | 2020 | |
| Convatec INC. | $27.84 | 2025 | |
| Mimedx Group, INC. | $25.04 | 2024 | |
| Argentum Medical | $23.72 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.67 | 2023 | Spevigo |
| Dusa Pharmaceuticals, INC. | $17.35 | 2019 | |
| Merz North America, INC. | $15.18 | 2020 | |
| Journey Medical Corporation | $14.80 | 2022 | |
| Epi Health, LLC | $10.91 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.